dr. reckamp on pivotal data in metex14-altered nsclc
Published 5 years ago • 242 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
2:24
dr. reckamp on met-targeting strategies in nsclc
-
1:11
dr. reckamp on targeted therapy options for rare mutations in nsclc
-
1:02
dr reckamp on amivantamab in egfr exon 20–mutated nsclc
-
0:49
dr. reckamp on molecular testing in lung cancer
-
1:25
dr. wolf on updated findings with capmatinib in metex14-mutant nsclc
-
0:59
dr. karen reckamp evaluates the predictive efficacy of the veristrat in nsclc
-
1:54
dr. le on the rationale for tepotinib in metex14-mutant nsclc
-
0:49
the importance of metex14 testing in nsclc
-
13:00
recognizing the role of capmatinib for metex14 in nsclc
-
1:36
dr. reckamp on cabozantinib plus erlotinib for advanced egfr-mutant nsclc
-
0:39
the patient experience is crucial in developing #lungcancer clinical trials
-
0:58
vision trial produces positive data in nsclc with met exon 14 mutations
-
1:10
dr. drilon on met-amplified lung cancer
-
2:08
christopher rechner, cnp | cleveland clinic kidney medicine
-
5:51
karen reckamp, md, ms: results in phase ii advanced lung cancer trial
-
2:00
dr. bazhenova on new developments in ret-rearranged nsclc
-
2:55
meet dr. evan zeitler: nephrologist
-
1:10
dr besse on mechanisms of acquired resistance in egfr advanced nsclc
-
3:35
the availability of met inhibitors for nsclc